Promoting Thrombolysis in Acute Ischemic Stroke
Authors:
- Maaike DirksMDMaaike Dirks
- Louis W. NiessenLNLouis W. Niessen
- Jeroen D.H. van WijngaardenJWJeroen D.H. van Wijngaarden
- Peter J. KoudstaalPKPeter J. Koudstaal
- Cees L. FrankeCFCees L. Franke
- Robert J. van OostenbruggeRORobert J. van Oostenbrugge
- Robbert HuijsmanRHRobbert Huijsman
- Hester F. LingsmaHLHester F. Lingsma
- Mirella M.N. MinkmanMMMirella M.N. Minkman
- Diederik W.J. DippelDDDiederik W.J. Dippel
- for the PRomoting ACute Thrombolysis in Ischemic StrokE (PRACTISE) InvestigatorsFIfor the PRomoting ACute Thrombolysis in Ischemic StrokE (PRACTISE) Investigators
- 1 May 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 42 (5) , 1325-1330
Abstract
Background and Purpose—: Thrombolysis with intravenous recombinant tissue plasminogen activator is an effective treatment for acute ischemic stroke, but the number of treatable patients is limited. The PRomoting ACute Thrombolysis in Ischemic StrokE (PRACTISE) trial evaluated the effectiveness of a multidimensional implementation strategy for thrombolysis with intravenous recombinant tissue plasminogen activator in acute ischemic stroke. Methods—: The PRACTISE trial was a national multicenter cluster-randomized controlled trial with randomization after pairwise matching. Twelve hospitals, both urban and community, academic and nonacademic, in the Netherlands participated. All patients admitted with stroke within 24 hours from onset of symptoms were registered. The intervention included 5 implementation meetings based on the Breakthrough Series model. The primary outcome was treatment with thrombolysis. Secondary outcomes were admission within 4 hours after onset of symptoms, death or disability at 3 months, and quality of life. Results—: Overall 5515 patients were included in the study' 308 patients (12.2%) in the control centers and 393 patients (13.1%) in the intervention centers were treated with thrombolysis (adjusted OR, 1.25; 95% CI, 0.93 to 1.68). Among the 1657 patients with ischemic stroke admitted within 4 hours from onset, 391 (44.5%) of 880 in the intervention centers were treated with thrombolysis and 305 (39.3%) of 777 in the control centers; the adjusted OR for treatment with thrombolysis was 1.58 (95% CI, 1.11 to 2.27). Conclusions—: An intensive implementation strategy increases the proportion of patients with acute stroke treated with thrombolysis in real-life settings. An apparently pivotal factor in the improvement of the treatment rate is better application of contraindications for thrombolysis.Keywords
This publication has 13 references indexed in Scilit:
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE)International Journal of Stroke, 2007
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2005
- CONSORT statement: extension to cluster randomised trialsBMJ, 2004
- Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic StrokeArchives of Neurology, 2004
- A systematic review of barriers to delivery of thrombolysis for acute strokeAge and Ageing, 2004
- Crossing the boundary: changing mental models in the service of improvementInternational Journal for Quality in Health Care, 1998
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988